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Interferon-regulatory factor 4 (IRF4) is essential for
the development of T helper 2 (Th2) and Th17 cells.
Herein, we report that IRF4 is also crucial for the
development and function of an interleukin-9 (IL-9)-
producing CD4+ T cell subset designated Th9.
IRF4-deficient CD4+ T cells failed to develop into
IL-9-producing Th9 cells, and IRF4-specific siRNA
inhibited IL-9 production in wild-type CD4+ T cells.
Chromatin-immunoprecipitation (ChIP) analyses re-
vealed direct IRF4 binding to the Il9 promoter in
Th9 cells. In a Th9-dependent asthma model, neu-
tralization of IL-9 substantially ameliorated asthma
symptoms. The relevance of these findings is
emphasized by the fact that the induction of IL-9
production also occurs in human CD4+ T cells
accompanied by the upregulation of IRF4. Our data
clearly demonstrate the central function of IRF4 in
the development of Th9 cells and underline the
contribution of this T helper cell subset to the patho-
genesis of asthma.
INTRODUCTION
Immune reactions are controlled by distinct subtypes of CD4+
T helper (Th) cells. Initially, it was thought that many immune
responses were strongly influenced by the interaction of T helper
1 (Th1) and Th2 cells and by their cross-regulatory properties, in
particular because of the production of cytokines interferon-g
(IFN-g) (Th1) and interleukin-4 (IL-4) (Th2). Infectious diseases
were found to elicit preferentially a Th1 cell response, whereas
parasitic infections provoke an expansion of Th2 cells. In addi-
tion, these Th cell populations are causally involved in the gener-
ation of autoimmune (Th1) and allergic (Th2) diseases. Increased
efforts have clarified the conditions of Th1 and Th2 cell develop-
ment and have revealed that the lineage-specific cytokines
IFN-g and IL-4 are also decisively involved in the respective Th192 Immunity 33, 192–202, August 27, 2010 ª2010 Elsevier Inc.cell subtype differentiation (Schmitt et al., 1994b; Seder and
Paul, 1994). The transcription factor T-bet (T-Box expressed in
T cells) is indispensable for the development of Th1 cells and
GATA-3 (GATA-binding protein 3) for Th2 cells (Szabo et al.,
2000; Zheng and Flavell, 1997). Several years ago, the next Th
cell subtype was characterized by the production of IL-17, and
accordingly they were termed Th17 cells (Stockinger and Veld-
hoen, 2007). Apart from directing the immune response to extra-
cellular pathogens such as Klebsiella orCandida, Th17 cells play
a crucial role in the course of autoimmune diseases such as
rheumatoid arthritis. The development of Th17 cells is promoted
by a combination of the cytokines transforming growth factor-b
(TGF-b) and IL-6. The transcription factor RORgt (RAR-related
orphan receptor gamma 2) directs the differentiation of Th17
cells (Ivanov et al., 2006), whereas deficiency in IRF4 prevents
their development (Bru¨stle et al., 2007; Huber et al., 2008), indi-
cating the important roles of these transcription factors for
generating Th cells (Lohoff andMak, 2005). Very recently, a fourth
Th cell-subtype that preferentially produces IL-9 was described,
and therefore these cells are termed Th9 cells (Dardalhon et al.,
2008; Veldhoen et al., 2008).
IL-9 is a pleiotropic cytokine originally termed p40, TCGFIII, or
MEA (Hu¨ltner et al., 1990). In addition to Th2 cells, mast cells and
eosinophils were shown to be sources for this cytokine (Gounni
et al., 2000; Hu¨ltner et al., 2000). With regard to murine CD4+
T cells, we showed that IL-9 secretion depends on IL-2, is syner-
gistically enhanced by a combination of TGF-b and IL-4, and is
inhibited by IFN-g (Schmitt et al., 1994a). Although we were
able to show that GATA-1 drives the expression of IL-9 in mast
cells, little is known about the transcriptional regulation of IL-9
production by CD4+ T cells and the differentiation of Th9 cells
(Stassen et al., 2007).
Functionally, IL-9 is critically involved in the resistance to para-
sites (Trichuris muris) and plays a detrimental role concerning
the pathogenesis of asthma, although the cellular source for
IL-9 during this disease is unknown (Khan et al., 2003; Temann
et al., 1998). Herein, we demonstrate that the transcription
factor IRF4 is essentially involved in Th9 lineage differentiation
by directly regulating the expression of the lineage-specific cyto-
kine IL-9. Furthermore, we provide evidence that Th9 cells
substantially contribute to the pathogenesis of asthma.
Figure 1. IRF4-Deficient CD4+ T Cells Fail to
Differentiate into Th9 Cells
Naive CD4+ T cells from either IRF4-deficient
(Irf4/) mice or their heterozygous littermates
(Irf4+/) were stimulated under Th1, Th2, Th9 or
Th17 cell-skewing conditions.
(A) Three days upon primary stimulation superna-
tants were collected and analyzed for the pres-
ence of IL-9.
(B) Expression of IL-9 and IL-4 was analyzed on
day 3 by FACS analyses in Irf4+/ and Irf4/
CD4+ T cells stimulated under Th9 promoting
conditions.
(C and D) 24 hr after re-stimulation on day six
supernatants were collected and subsequently
analyzed for the presence of IL-9 (C) and IL-4 (D).
(E) IFN-g was determined in Irf4+/ and Irf4/
CD4+ T cells after activation under Th9-promoting
conditions. See also Figure S1 and S6. Shown is
one representative from three independent exper-
iments ± SEM. All experiments were performed in
triplicates. Amounts that are not detectable are
indicated by an asterisk.
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IRF4 Is Crucial for Th9 Cell DevelopmentRESULTS
IRF4 Deficiency Blocks CD4+ T Cell Differentiation
into Interleukin 9-Producing Th9 Cells
We showed that IL-9 production of TCR-triggered naive CD4+
T cells can be synergistically enhanced by a combination of
TGF-b and IL-4 (Schmitt et al., 1994a). Recently, such IL9-
producing T cells were classified as T helper 9 (Th9) cells (Dardal-
hon et al., 2008; Veldhoen et al., 2008). To examine the contribu-
tion of IRF4 to the development of Th9 cells, we differentiated
purified naive CD4+CD62Lhi cells from IRF-4-deficient (Irf4/)
mice and from Irf4+/ littermates under Th1-, Th2-, Th17 cell-
skewing conditions or in the presence of TGF-b and IL-4 for
Th9 cell development. To analyze the capability of the different
Th cell subtypes to produce IL-9, we either collected superna-
tants on day 3 of culture or restimulated them on day 5 for addi-
tional 24 hr as described in the Experimental Procedures.
Whereas Irf4+/ Th2 and Th9 cells showed substantial IL-9
production on day 3 (Figures 1A and 1B), only Th9 cells retainedImmunity 33, 192–202this property upon restimulation on day 6
after primary activation (Figure 1C). In
sharp contrast, T cells from Irf4/ mice
barely produced this cytokine (Figures
1A–1C) on day three and showed no
detectable IL-9 production upon restimu-
lation. Remarkably, Th9 cells showed
some IL-4 expression (Figure 1D) but
did not produce any detectable amounts
of IL-5 or IL-13 (data not shown). In sharp
contrast to Irf4+/ Th9 cells, Irf4/ T cells
showed strong IFN-g production upon
stimulation under Th9 cell-promoting
conditions (Figure 1E). In agreement
with these results, Irf4/ CD4+ T cells
displayed a substantial upregulation of
the Th1 cell-specific transcription factorT-bet, in contrast to Irf4+/ CD4+ T cells (see Figures S1A and
S1B available online). To further assess the importance of IRF4
for IL-9 production by Th9 cells, we analyzed the induction of
IRF4 under Th1-, Th2-, and Th9 cell-skewing conditions.
Although, IRF4 was upregulated in Th2 cells from day 3 upon
stimulation, Th9 cells expressed increasing amounts of IRF4
protein (see Figure S2) accompanied by high IL-9 expression
on day 3. Notably, stimulation under Th9 cell-differentiating
conditions had no effect on RORgt mRNA expression (data not
shown).
To gain further insights into the relation between IRF4 and IL-9
expression, we performed combined intracellular staining of
IRF4, IL-4, and IL-9. Stimulation of naive CD4+ T cells under
Th9 cell-skewing conditions resulted in 80% IRF4-positive
T cells (Figure 2A) according to isotype control staining. Con-
sistent with our previous results, IL-9-producing T cells were
only found within the IRF4-positive population and IL-9 pro-
duction positively correlated with expression of IRF4 (Figures
2A–2D)., August 27, 2010 ª2010 Elsevier Inc. 193
Figure 2. IRF4 Expression Is Indispensable
for IL-9 Production by Th9 Cells
Naive C57Bl/6 Irf4+/+ CD4+ T cells were stimulated
under Th9 cell-promoting conditions.
(A) On day 3, Th9 cells were intracellular stained for
the expression of IRF4.
(B) By gating on IRF4-negative (a) (defined by
isotype staining; doted line) and IRF4-positive (b)
T cells, the cells were further analyzed for the
production of IL-4 and IL-9.
(C) For analyzing the correlation between IRF4
expression and IL-9 production by Th9 cells,
T cells were subdivided into four regions, each
representing different expression of IRF4: a, no
expression (according to isotype control; dotted
line); b, low expression; c, intermediate expres-
sion; and d, high expression.
(D) Upon gating on these individual regions, the
magnitude of IL-9 expression was defined by the
mean fluorescence intensity (MFI) measured by
flow cytometry. See also Figure S2. Shown is
one representative experiment of two indepen-
dent experiments performed in triplicates ± SEM.
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IRF4 Is Crucial for Th9 Cell DevelopmentOnemay argue that the defect of Irf4/ T cells in IL-9 produc-
tion represents an epiphenomenon due to altered T cell develop-
ment in Irf4/ mice. To rule out this possibility and to further
corroborate the crucial role of IRF4 for Th9 cell-mediated IL-9
production, we transfected naive C57Bl/6 (B6) wild-type CD4+
T cells with small interfering RNA (siRNA) either specific for
IRF4 (IRF4-siRNA) or an unspecific scrambled control siRNA
(Scr-siRNA) as described previously (Bru¨stle et al., 2007).
Notably, transfection of B6 wild-type CD4+ T cells led to
substantial reduction of IRF4 protein expression (Figure 3A)
accompanied by strongly decreased IL-9 production and greatly
enhanced IFN-g production (Figures 3B and 3C). Specificity of
this gene targeting is supported by an unaltered ability of the
cells to produce IL-2 (Figure 3D). To determine the requirement
of IRF4 for the maintenance of a stable Th9 cell phenotype, we
silenced IRF4 expression by specific siRNA on day 3, when
high amounts of IL-9 production can be measured. Notably,
upon restimulation on day 5, the reduction of IRF4 by siRNA194 Immunity 33, 192–202, August 27, 2010 ª2010 Elsevier Inc.led to a substantial reduction of IL-9
production accompanied by a strong
upregulation of IFN-g expression (see
Figure S3). This demonstrates that con-
stant high expression of IRF4 is needed
to establish and maintain Th9 cell devel-
opment and function. Taken together,
these results demonstrate that IRF4 is
essential for the developmental program
of IL-9-producing T cells.
IRF4 Controls IL-9 Production
of Th9 Cells via Direct Binding
to Its Promoter
In order to examine the influence of IRF4
on the Il9 promoter, we performed
reporter gene assays by using expression
vectors coding either for IRF4 or an IRF4defect mutant (IRF4DRD) in which the regulatory domain was
deleted (Negishi et al., 2005). Cotransfection experiments using
CD4+ T cells revealed that only the combination of full-length
IRF4 and an Il9 promoter-luciferase plasmid led to transactiva-
tion. Neither ectopic expression of IRF4DRD nor of an empty
plasmid vector (mock) could induce the expression of the
reporter gene (Figure 4A). These observations allowed us to
conclude that IRF4 essentially contributes to the expression of
the Il9 gene in CD4+ T cells most possibly by interacting with
PU.1 (Chang et al., 2010). In an attempt to detect potential direct
binding of endogenous IRF4 to the Il9 promoter in differentiating
Th9 cells, we performed chromatin immunoprecipitation (ChIP)
assays. To this end, we stimulated naive B6 wild-type CD4+
T cells under Th9 cell-skewing conditions. On day 2 of culture,
the cells were harvested and fixed, and ChIP was performed
with an IRF4-specific antibody as described in the Experimental
Procedures. As shown in Figure 4B, coprecipitation of the
Il9 promoter occurred when antibodies specific for IRF4 were
Figure 3. Short Interference RNA-Mediated
Silencing of IRF4 Decreases the Production of IL-
9, whereas IL-2 Production Is Unaffected
Analysis of IRF4 (A) protein expression, IL-9 (B), IFN-g (C)
and IL-2 (D) production by naive C57Bl/6 Irf4+/+ CD4+
T cells upon siRNA-mediated gene targeting of IRF4.
Freshly isolated naive Irf4+/+ CD4+ T cells were transfected
with IRF4-specific short interference RNA (siRNA) (IRF4-
siRNA) or control ‘‘scrambled’’ siRNA (Scr-siRNA). Subse-
quently cells were stimulated under Th9-promoting condi-
tions. (A) shows an immunoblot of IRF4 expression and
b-actin as loading control. After 72 hr, IL-9 (B), IFN-g (C),
and IL-2 (D) production were assayed in the supernatants
by ELISA. See also Figure S3. (A) shows one representa-
tive experiment of two independent experiments. Speci-
ficity of the antibody was assessed by analyses of protein
extracts from Irf4/ CD4+ T cells (data not shown). In (B),
(C), and (D) the mean values of two independent experi-
ments performed in triplicates ± SEM are shown.
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IRF4 Is Crucial for Th9 Cell Developmentused, but not with isotype control antibody. This result formally
establishes IRF4 binding to the Il9 promoter. Collectively, these
results show that IRF4 directs Th9 cell development via binding
to the Il9 promoter.
Human Naive CD4+ T Cells Can Also Be Programmed
byTGF-b and IL-4 toDifferentiate into an IL-9-Producing
T Helper Cell Subset
In contrast to the rapidly growing number of reports on different
murine T helper cell subsets, exiguous data are published with
regard to their human counterparts. To ascertain the existence
of a human IL-9-producing T helper cell subset, we isolated
naive CD4+ T cells from human cord blood and stimulated these
cells in the absence (Ø) or presence of the designated cytokines
(Figure 5). On day 3, a strong expression of IL-9 was detected
by quantitative real time-PCR analyses (qRT-PCR) (Figure 5A).
This was corroborated by detection of IL-9 in the supernatants
(Figure 5C) via cytometric Bead Array (BD, Heidelberg, Germany)
and flow cytometry. To correlate production of IL-9 with expres-
sion of IRF4, we performed qRT-PCR for IRF4 mRNA expression
(Figure 5B) as well as flow cytometric analyses to detect IRF4
protein with the same CD4+ T cell preparations (Figure 5D).
In line with the results obtained in the murine system, human
naive CD4+ T cells stimulated in the presence of IL-4 and
TGF-b showed enhanced IL-9 production, which was accompa-
nied by strong expression of IRF4. These results indicate thatImmunity 33, 1a comparable developmental program of Th9
cells exists in humans and mice.
Th9 Cells Crucially Contribute
to the Development of Asthma
Recently, a contribution of Th9 cells in the resis-
tance to worm infections was suggested.
In addition, IL-9 was shown to be involved
in the pathogenesis of asthma, and it was
assumed that Th2 cells and/or mast cells served
as a source of this cytokine. Hence, Th9 cells
could represent an important source of IL-9
during this disease. In order to assess thisassumption and to disclose the pathophysiological role of Th9
cell responses in vivo, we established an adoptive transfermodel
of Th9 cells comparable to the Th2 cell-induced allergic airway
disease model (see Figure S4). To this end, we isolated naive
CD4+ T cells from BALB/c DO11.10 mice and stimulated them
in vitro under Th2- or Th9-skewing conditions as described in
the Experimental Procedures. On day 5 of culture, the Th2 or
Th9 cells were transferred to RAG2-deficient (Rag2/) mice,
which were simultaneously treated by intranasal application of
a neutralizing IL-9 antibody. Within six consecutive days, the
mice were subsequently exposed to the nebulized allergen
ovalbumin. Baseline values of pulmonary resistance (RL) and
dynamic compliance (Cdyn) were not statistically different
between the groups studied. The mice that had received Th2
cells developed severe asthma symptoms characterized by
increased airway reactivity to methacholine (MCh) (Figure 6A),
increased goblet cell numbers (PAS-positive cells), and
enhanced eosinophil numbers in the broncho-alveolar lavage
(BAL) (Figure 6B) after airway challenge. Likewise, Rag2/
mice adoptively transferred with Th9 cells showed identical
asthma symptoms upon antigen exposure.
Treatment of Th2 cell recipient Rag2/ mice with a neutral-
izing IL-9 antibody only slightly ameliorated asthma symptoms,
represented by AHR (Figure 6A), eosinophil numbers in BAL
(Figure 6B), mucus-producing goblet cells (PAS-positive cells;
Figure 6C), and histological score (Figure 6D). In sharp contrast,92–202, August 27, 2010 ª2010 Elsevier Inc. 195
Figure 4. IRF4 Regulates IL-9 Production via Direct Binding to the Il9
Promoter
(A) CD4+ T cells were transfected with a plasmid coding for IRF4 (IRF4), an IRF4
mutant (IRF4DRD) unable to interact with defined transcription factors or with
the corresponding empty vector (mock) in combination with a constant
amount of Il9 promoter-luciferase construct. Twenty-four hours after stimula-
tion, cell protein extracts were prepared and luminescence was measured in
triplicates.
(B) Chromatin from CD4+ T cells stimulated for 48 hr in the presence of IL-4,
and TGF-bwas prepared and precipitated with anti-IRF4 or the respective iso-
type control as outlined in the Experimental Procedures. qRT-PCR analysis
(30 cycles) for the coprecipitated Il9 promoter was performed. Representative
of three independent experiments ± SEM with equivalent results are shown in
(A) and (B).
Immunity
IRF4 Is Crucial for Th9 Cell Developmentapplication of the neutralizing IL-9 antibody to Th9 cell recipi-
ent Rag2/ mice resulted in a profound amelioration of Th9
cell-mediated asthma (Figures 6A–6D). These data clearly
indicate the stability of IL-9-producing Th9 cells in vivo and
that the pathophysiological role of Th9 cells in allergic asthma
is predominantly mediated by IL-9. Presumably, this cytokine
plays only a marginal role for the asthma-promoting activ-
ity of Th2 cells. Collectively, our results indicate that Th9
cell-derived IL-9 crucially contributes to the pathogenesis of
asthma.196 Immunity 33, 192–202, August 27, 2010 ª2010 Elsevier Inc.Deficiency in Th9 Cell Development Prevents Irf4/
Mice from Asthma
Because of the asthma-promoting capacity of Th9 cells and the
disability of IRF4-deficient cells to differentiate into Th9 cells
in vitro, we investigated whether IRF4-deficient mice are resis-
tant to this chronic lung disease. To this end, we immunized
Irf4/, Irf4+/, and wild-type (Irf4+/+) C57Bl/6 mice with oval-
bumin as delineated in Figure S5. Three out of four WT mice
showed severe asthma-provoked eosinophilia as demonstrated
by high numbers of CCR3+Gr1+ eosinophils in the BAL (Figures
7A and 7B). In sharp contrast, all Irf4/mice showed absolutely
no eosinophilia (Figure 7). Interestingly, mice heterozygous in
IRF4 deficiency displayed an intermediate phenotype according
to the asthma symptoms provoked by challenging via oval-
bumin-nebulization. Notably, the transfer of in vitro-generated
Th9 cells from OT-II mice completely restored all asthma symp-
toms clearly demonstrating the crucial importance of IRF4 in
the development of Th9 cells in vivo and their essential role in
the course of asthma.
DISCUSSION
Th9 cells represent a new member of the still-growing T helper
cell family. However, the transcriptional regulation of the Th9
cell-type cytokine IL-9 was still elusive. Herein, we identified
IRF4 as the essential transcription factor that drives IL-9 pro-
duction and Th9 cell differentiation. Previous studies disclosed
a role for IRF4 in Th2 cell as well as Th17 cell differentiation, high-
lighting the crucial importance of this transcription factor in T
helper cell lineage differentiation (Bru¨stle et al., 2007; Lohoff
et al., 2002; Rengarajan et al., 2002; Tominaga et al., 2003). Inter-
estingly, depending on the interaction partner and the DNA
binding motif, IRF4 can act as a transcriptional activator as
well as a transcriptional repressor (Pongubala et al., 1992;
Yamagata et al., 1996). IRF4 was shown to directly promote
IL-4 expression by physical interaction with members of the
NFAT family of transcription factors in T helper cells (Hu et al.,
2002; Rengarajan et al., 2002). In B cells, IRF4 can exert its
function as a transcriptional activator by interacting with the
transcription factors PU.1 and STAT6 (signal transducer and
activator of transcription 6) (Brass et al., 1996; Gupta et al.,
1999). These diversified options of transcriptional regulation
relying on both the DNA binding site and most notably the inter-
action partner may explain the multifaceted scope of IRF4 in
T helper cell differentiation. Depending on the cytokine milieu,
the expression of distinct interaction partners for IRF4 seems
to determine the fate of T helper cell differentiation.
Regarding Th9 cell-inducing cytokines, it was shown that Th9
cells develop under a carefully balanced influence of IL-4 and
TGF-b. Upon neutralization of IL-4, the IL-9-inducing capacity
of TGF-b was strongly impaired. This finding was confirmed
with IL-4-deficient T cells that show greatly reduced IL-9 produc-
tion upon stimulation (Monteyne et al., 1997; Schmitt et al.,
1994a). Therefore, both cytokines have to act in concert and
thus are mandatory for Th9 cell differentiation. IL-4 receptor
signaling is crucial for Th2 cell differentiation by driving the
expression of STAT6 (Takeda et al., 1996). The importance of
STAT6 relies on its ability to drive the expression of the Th2
cell-specific transcription factor GATA-3 (Kurata et al., 1999).
Figure 5. Th9 Cell Differentiation of Human Naive
CD4+ T Cells Correlates with IRF4 Expression
Naive human CD4+ T cells isolated from cord blood were
stimulated in the presence of the indicated cytokines for
3 days. For analyzing Th9 cell differentiation, IL-9 mRNA
(A) and IRF4 mRNA (B) expression were analyzed by
qRT-PCR. Respectively, IL-9 production was measured
by cytometric bead assay (C) and IRF4 expression was
analyzed by flow cytometry (D) as outlined in the Experi-
mental Procedures. In (A)–(C), mean values of two
independent experiments ± SEM are given. ELISAs were
performed in triplicates.
Immunity
IRF4 Is Crucial for Th9 Cell DevelopmentHowever, in contrast to Th2 cells, naive T cells stimulated under
Th9 cell-polarizing conditions did not show any significant
GATA-3 expression potentially due to TGF-b-mediated counter-
action (Dardalhon et al., 2008; Gorelik et al., 2000; Kulkarni and
Karlsson, 1997). On the other hand, it was shown with STAT6-
deficient cells that STAT6 is indispensible for Th9 cell differenti-
ation (Dardalhon et al., 2008). These findings suggest that TGF-b
inhibits IL-4-mediated upregulation of GATA-3 while the expres-
sion of STAT6 is unaffected under these conditions. Notably,
STAT6 is not only capable to counteract the FoxP3-inducing
capacity of TGF-b (Dardalhon et al., 2008) but moreover can
drive the expression of IRF4 (Pernis, 2002), thereby possibly
promoting Th9 cell differentiation.
TGF-b is well known for its immunosuppressive function (Wahl
and Chen, 2003). Genetic ablation of TGF-b as well as interfer-
ence with TGF-b signaling causes spontaneous differentiation
of Th1 and Th2 cells (Gorelik et al., 2000). Notably, TGF-b was
shown to be essentially involved in Th17 cell differentiation by
inhibiting both the expression of STAT4 andGATA3, thereby pre-
venting the differentiation of Th1 and Th2 cells and concurrently
facilitating Th17 cell development. Contributory to Th9 cell
development, TGF-b and IL-4 mutually prevent the expression
of IFN-g, thereby impeding its inhibitory function on IL-9 produc-
tion (Schmitt et al., 1994a). Furthermore, by inducing the expres-Immunity 33, 1sion of IRF4, TGF-b and especially IL-4 further
neutralize the inhibitory effect of endogenously
produced IFN-g.
IL-9 was found to play an important role with
respect to the resistance to worm infections
(Behnke et al., 1993; Khan et al., 2003; Leech
and Grencis, 2006; Richard et al., 2000).
Because IRF4 is indispensible for the develop-
ment of Th9 cells, it is notable that IRF4-deficient
mice are incapable of expelling N. brasiliensis
(Honma et al., 2008). This suggests that protec-
tive IL-9 production presumably by Th9 cells is
lacking in the absence of IRF4. Besides its bene-
ficial properties concerning Helminth infections,
IL-9 plays a detrimental role in several allergic
diseases including the pathogenesis of asthma
(Barnes, 2008; Herrick and Bottomly, 2003;
Holgate and Polosa, 2008). In humans, polymor-
phisms in the chromosomal region coding for
IL-9 correlate with the development of atopy
and asthma (Doull et al., 1996; Noguchi et al.,1997; Postma et al., 1995). Consistently, one report provides
evidence for an interrelation between a polymorphism in the Il9
receptor gene and bronchial hyperresponsiveness or asthma
(Holroyd et al., 1998). Likewise, mice showing hyporesponsive
airways carry polymorphisms at the Il9 locus when compared
to hyperresponsive DBA/2J mice (Nicolaides et al., 1997).
Furthermore, IL-9 production upon protein antigen exposure
seems to strictly rely on the presence of T cells, implicating that
Th2 cells were the source of this IL-9 (Monteyne et al., 1997).
In a comparative analysis of Th2 and Th9 cells in amurine asthma
model, we could showherein that both T cell subtypes induce the
same pattern of symptoms. However, neutralization of IL-9 could
only abrogate the asthma-inducing properties of Th9 cells,
whereas Th2 cells were marginally affected. This demonstrates
that the asthma-promoting capability by producing IL-9 and the
phenotype of Th9 cells both are stable in vivo. In addition, the
inability to induceasthmasymptoms in Irf4/miceclearly under-
scores the central importance of IRF4 for the development of
Th9 cells in vivo and for the resulting IL-9-mediated asthma
symptoms. This was further substantiated by the fact that the
transfer of Irf4+/+ Th9 cells prior to challengewithOVAcompletely
restored the asthma-accompanying eosinophilia and it excluded
thepossibility that IRF4deficiency in anyother cells thanTh9cells
plays a prominent role in this scenario.92–202, August 27, 2010 ª2010 Elsevier Inc. 197
Figure 6. Neutralization of IL-9 Strongly Amelio-
rates Th9 Cell-Induced Asthma
Rag2/mice (n = 6) were adoptively transferred with Th2
or Th9 cells and challenged with nebulized OVA in the
absence or presence of neutralizing anti-IL-9 as outlined
in the Experimental Procedures and Figure S4. Airway
resistance (A) and numbers of eosinophils in BAL fluid
(B) were measured in mice 24 hr after the last airway
challenge. In (A), means ± SEM are given. In (B), bars
represent the mean. Additionally, tissue inflammation
was evaluated 24 hr after the last challenge with PAS
staining for goblet cells (C) and hematoxylin and eosin
staining (H&E) (D). Slides were scored for peribronchial
inflammation with a semiquantitative score from 0 to 4.
The numbers of mucus-positive cells scored 1 per milli-
meter basement membrane were quantified for each
group as described in the Experimental Procedures.
Mean ± SEM are given.
Immunity
IRF4 Is Crucial for Th9 Cell DevelopmentCollectively, these findings demonstrate that Th9 cell-derived
IL-9 is an important inducer of asthmatic symptoms equivalent to
IL-4. In addition, we show that IRF4 is crucially involved in Th9
cell development. Given that IRF4 was also found to be essen-
tially involved in Th2 cell development, this transcription factor
represents a promising target for the treatment of chronic lung
diseases.
EXPERIMENTAL PROCEDURES
Mice
Mice of strain C57Bl/6 (B6) were obtained fromCharles River Laboratories and
bred in our own animal facility. DO11.10 mice, transgenic for the OVA323-339-
specific TCR-ab (Murphy et al., 1990) on a BALB/c genetic background,
were a gift from D.Y. Loh (Nippon Research Center) through M. Kopf and
were bred in our own animal facility. IRF4-deficient mice (Irf4/) were
provided by W. Mittru¨cker (Mittru¨cker et al., 1997). RAG2-deficient mice on
a BALB/c background were bred in our own animal facility under special path-
ogen-free conditions. Males and females were used at the age of 6–12 weeks.
Ethics Statement
This study was conducted according to the principles expressed in the Decla-
ration of Helsinki. The study was approved by the Institutional Review Board of
the University of Heidelberg. All patients provided written informed consent for
the collection of samples and subsequent analysis.
Cytokines, Antibodies, and Reagents
Mouse rIL-4 was affinity purified with a column with anti-mIL-4 (11B11) mAb
bound to Sepharose. Hybridoma cells producing CD4 mAb GK1.5 and human
CD3 mAb OKT3 were obtained from American Type Culture Collection (ATCC198 Immunity 33, 192–202, August 27, 2010 ª2010 Elsevier Inc.TIB 207; Manassas, VA). Anti-mIL-4 (11B11) was a gift
from W. Paul (National Institutes of Health, Bethesda,
MD) (Ohara and Paul, 1985). Purified rmIL-12 (Lot MRB
91092) was a gift of M.K. Gately (Hoffmann-La Roche,
Nutley, NJ). Anti-mIL-4 (BVD4-1D11) and BVD6-24G2
were gifts from A. O’Garra (National Institute for Medical
Research, Mill Hill, UK). Recombinant murine (m)IL-9 and
hamster mIL-9 mAb C12 were given to us by J. Van Snick
(Ludwig Institute, Brussels, Belgium). Rat mIL-9 mAb
229.4 was generated by the fusion of spleen cells of
a Lewis rat immunized with mIL9. Hamster CD28 mAb
37.51 (Gross et al., 1992) was given to us by J.P. Allison
through G. Leclercq (University of Gent, Gent, Belgium).
If required, mAbs were affinity purified with protein G
sepharose (Pharmacia) and coupled with FITC or Biotin.
The antigenic OVA peptide (OVA323–339) was synthesizedon an Applied Biosystems peptide synthesizer (Foster City, CA). Porcine
TGF-beta1, murine IL-6, and recombinant human IL-4 were obtained from
R&D Systems. In addition, we used the following antibodies: mouse IFN-y
mAb XMG 1.2 (Cherwinski et al., 1987), anti-IFN-g-PE (XMG1.2; eBioscience),
CD3mAb 145-2C11 (Leo et al., 1987), anti-IRF4 (rabbit, Cell Signaling), normal
rabbit IgG (Cell Signaling), Alexa488-conjugated (F(ab’)2 fragment of goat anti-
rabbit IgG (Invitrogen), APC-conjugated anti-mouse IL-9 (RM9A4; BioLegend),
APC-conjugated rat IgG1, k (BioLegend), Anti-IL-4-PE (11B11; eBioscience),
rat IgG1 (BD), and purified mouse anti-human CD28 (BD).
CD4+ T Cell Isolation
Murine naive CD4+CD25- T cells (CD4+ T cells; GK1.5-FITC) were isolated as
described previously (Bopp et al., 2005; Bru¨stle et al., 2007).
Human naive CD4+ T cells were isolated from cord blood. PBMC were puri-
fied with Ficoll density gradient centrifugation. Subsequently, CD4+ T cells
were isolated by positive selection with high-gradient MACS (Miltenyi Biotec)
in accordance with the manufacturer’s instructions.
Stimulation and Differentiation of Murine T Cells
Murine naive CD4+ T cells were cultured in Iscove’s modified Dulbecco’s
medium (Sigma). Medium was supplemented with 5% FCS, 1% penicillin/
streptomycin, 1% L-glutamin and Na-pyruvat and 50 mM b-mercaptoethanol.
Cells were stimulated with plate-bound anti-CD3 (3 mg/ml) and anti-CD28
(5 mg/ml). For T cell differentiation, cells were stimulated in the presence of
the following cytokines and antibodies. Th1: 3000 U/ml IL-12, 1000 U/ml Pro-
leukin (recombinant human IL-2), 10 mg/ml anti-IL-4 (11B11); Th2: 1000 U/ml
IL-4, 100 U/ml IL-6, 20 mg/ml anti-IFN-g (XMG1.2); Th17: 5 mg/ml anti-IL-4,
5 mg/ml anti-IFN-g, 50 ng/ml mIL-6, 0,5 ng/ml porcine TGF-b1; Th9: 1000 U/ml
IL-4, 100 U/ml IL-6, 20 mg/ml anti IFN-g (XMG1.2), and 1 ng/ml pTGF-b1.
Because IL-9mRNA production of naive T cells was found to reach a plateau
level after 48 hr (see Figure S6), supernatants were used on day 3 for
Figure 7. IRF4-Deficient Mice Are Resistant to Asthma
Wild-type C57Bl/6 (Irf4+/+), Irf4+/, and Irf4/ mice (n = 4 per group) were
immunized in accordance with the protocol delineated in Figure S5 and out-
lined in the Experimental Procedures. In brief, mice were only challenged
(Chal) with ovalbumin to define a basic level in the absence of inflammation
or sensitized and challenged (Sense/Chal). Twenty-four hours after the last
challenge, broncho-alveolar lavage (BAL) from mice that received either PBS
(Ø) or Th9 cells from OT-II mice (Th9) i.v. were stained for CCR3 and Gr1 so
that percentages of eosinophils could be assessed. (A) To demonstrate the
specificity of CCR3 and Gr1 staining for eosinophils, CCR3+Gr1+ cells in the
BAL were gated and displayed in red according to size (FSC) and granularity
(SSC). Percentages of CCR3+Gr1+ eosinophils in the BAL are indicated. One
representative mouse from each group is shown. (B) Based on CCR3 and
Gr1 expression the percentage of eosinophils in the BAL of each mouse was
evaluated. Three mice which were sensitized and challenged did not show
any symptoms of asthma (empty dots), but the percentages of eosinophils
were included in the calculation of the arithmetic mean (Mean; black bar).
Each dot represents a single mouse.
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IRF4 Is Crucial for Th9 Cell Developmentdetermining primary IL-9 secretion by IL-9-specific ELISA, and activated
T cells were used at this time point for intracellular FACS staining.
For secondary stimulation, T helper cells were harvested on day 5 and either
restimulated with anti-CD3 and anti-CD28 or restimulated with soluble
anti-CD3 (3mg/ml; 145-2C11) and mitomycin C-treated (60 mg/ml/107 cells,
30 min) A20 B-tumor cells as accessory cells for the indicated time points
for detecting the indicated cytokines.
Stimulation and Differentiation of Human T Cells
Human naive CD4+ T cells from cord blood were cultured in X-Vivo 15-Medium
(Lonza Vervier). Cells were stimulated with plate-bound anti-CD3 (1 mg/ml,
OKT3) and anti-CD28 (2 mg/ml, CD28.2). For Th9 cell differentiation, cells
were stimulated in the presence of the following cytokines: human recombi-
nant IL-4 (20 ng/ml), human recombinant IL-2 (Proleukin; 100 U/ml), and
porcine TGF-b1 (1 ng/ml). Comparable to murine Th9 cells, IL-9 production
of human T cells was found to reach a plateau level after 3 days. Therefore,
we collected supernatants at this time to determine IL-9 production by using
Cytometric Bead Array (CBA, BD). At this time point, activated T cells were
used for intracellular FACS staining and qRT-PCR.
Lymphokine Assays
Human cytokines in cell culture supernatants were assayed with BD Cytomet-
ric Bead Array (CBA) in combination with human IL-9 Capture Beads B6.
Mouse cytokines were assayed by specific ELISA. To detect IL-2, we used
mAb JES6-1A12 (1mg/ml) and biotinylated mAb JES6-5H4 bio (1 mg/ml) (BD).
IL-9 was detected by mAb 229.4 (1 mg/ml) and biotinylated mAb C12 (1 mg/ml).
This ELISA detects biologically active mIL-9, as confirmed with an IL-9-
specific bioassay (Schmitt et al., 1989). For the detection of murine IL-4, we
used the following combination of Abs: IL-4, BVD4-1D11, and BVD6-24G2
(Abrams et al., 1992). IFN-g was detected with mAb R46A2 and biotinylated
mAb AN18.17.24. ELISAs were evaluated in accordance with reference stan-
dard curves by using known amounts of the specific cytokine.
mRNA Detection
RNA was isolated with Trizol (Invitrogen) and cDNA was synthesized with
RevertAid M-MuLV reverse transcriptase following the recommendations of
the supplier (MBI Fermentas). Quantitative qRT-PCRs were performed with
the following oligonucleotides:
Murine HGPRT forward: 50-GTT GGA TAC AGG CCA GAC TTT GTT G-30
Murine HGPRT reverse: 50GAG GGT AGG CTG GCC TAT AGG CT-30
Murine IRF4 forward: 50-ACG CTG CCC TCT TCA AGG CTT-30
Murine IRF4 reverse: 50-TGG CTC CTC TCG ACC AAT TCC-30
Murine T-bet forward: 5‘-CAA CAA CCC CTT TGC CAA AG-3‘
Murine T-bet reverse: 5‘-TCC CCC AAG CAG TTG ACA GT-3‘
Murine IL-9 forward: 50-CTG ATG ATT GTA CCA CAC CGT GC-30
Murine IL-9 reverse: 50-GCC TTT GCA TCT CTG TCT TCT GG-30
Human EF1a- forward: 50-GAT TAC AGG GAC ATC TCA GGC TG-30
Human EF1a reverse: 50-TAT CTC TTC TGG CTG TAG GGT GG-30
Human IL-9 forward: 50-GTG CCA CTG CAG TGC TAA TGT-30
HumanIL-9 reverse: 50-CTC TCA CTG AAG CAT GGT CTG G-30
Human IRF4 forward: 50-GAA GCC TTG GCG TTC TCA GAC-30
Human IRF4 reverse: 50-CGT ATG TCC ATG GGA GAT CCG-30
Except murine IL-9 Chip2, all oligonucleotides were chosen to span at least
one intron at the level of genomic DNA. qRT-PCR analyses for quantifying the
expression of murine IRF4, murine IL-9, murine HGPRT, human IRF4, human
IL-9, and human EF1a mRNAs were performed in triplicates on an iCycler
(Bio-Rad) with SYBR GreenER (Invitrogen). After normalization of the data
according to the expression of HGPRT (murine) or EF1alpha (human) mRNA,
the relative expression of IRF4 and IL-9 mRNAs were calculated.
Intracellular Staining
For intracellular staining of IRF4, IFN-g, IL-9, and IL-4, murine and human naive
CD4+ T cells were stimulated for 72 hr as outlined in ‘‘Stimulation and Differen-
tiation of Murine [Human] T Cells’’ (Experimental Procedures). On day 3, Bre-
feldinA (Sigma) was added to the cells. Four hours later, cells were harvested,
washed with PBS and surface stained. Fixation and permeabilization wasImmunity 33, 192–202, August 27, 2010 ª2010 Elsevier Inc. 199
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stained for IRF4 (rabbit IgG isotype control), IL-9 (and rat IgG isotyp control),
IFN-g, and IL-4 (and rat IgG isotyp control). Alexa Fluor 488-labeled anti-rabbit
IgG (Invitrogen) was used as secondary antibody for visualization of anti-IRF4
mAb and the respective isotype control. The relative nuclear expressions of
IRF4, IFN-g, IL-9, and IL-4 were determined by FACS-analysis by subtracting
mean values of the respective Isotype control staining.
siRNA
CD4+ T cells from C57Bl/6 wild-type mice were isolated from splenocytes as
described above. Freshly prepared cells were transfected with 400 pmol of
IRF4-specific siRNA or ‘‘scrambled’’ control siRNA (for sequence see Bru¨stle
et al., 2007). In brief, 2 3 106 cells were transfected in 100 ml mouse T cell
Nucleofector solution (Amaxa). Upon stimulation for 16 hr with anti-CD3 and
anti-CD28, the expression of IRF4 was analyzed by specific immunoblot anal-
ysis. On day 3, we collected supernatants to determine IL-9 and IL-2 produc-
tion by ELISA.
Alternatively, naive wild-type CD4+ T cells from C57Bl/6 mice were stimu-
lated under Th9 cell-promoting conditions. On day 3, cells were either trans-
fected with 400pmol of IRF4-specific siRNA or ‘‘scrambled’’ control siRNA
as described above. Supernatants were collected 24 hr upon re-stimulation
on day 5 with a combination of anti-CD3 and anti-CD28 and the capability to
produce IL-9 and IFN-g was assayed by specific ELISA.
Immunoblot Analysis
CD4+ T cells were lysed in 80 ml RIPA-Puffer supplemented with proteinase
inhibitor. A total of 10 mg of lysates were fractionated by SDS-PAGE. After
transfer on nitrocellulose membrane, protein was analyzed by immunoblotting
with goat polyclonal anti-IRF4 (M17) (Santa Cruz Biotechnology). Specificity of
this antibody was assayed with protein extracts from Irf4/ cells. Detection of
b-Actin served as a control.
Luciferase Reporter Assay
A total of 23 106 naive CD4+ T cells were transfected with 10 mg of the reporter
vector coding for the Firefly Luciferase (pGL3 basic; Promega) under the
control of the Il9 promoter (Stassen et al., 2007). Additionally, cells were trans-
fected with 2.5mg of the IRF4 or IRF4 DRD (provided by T. Taniguchi, Negishi
et al., 2005); both in pcDNA 3.1+ (Invitrogen) and 300 ng of pRL-TK plasmid.
After Amaxa nucleofection, cells were stimulated with 1 mM Ionomycin and
20 ng/ml PMA for 24 hr. Cells were harvested and washed with PBS, and rela-
tive Il9 promoter activity was measured in relative light units (RLUs) in accor-
dance with the manufacturer’s instructions.
Chromatin Immunoprecipitation Assay
Upon stimulation under Th9 cell conditions, for 2 days 33 107 cells were fixed
with formaldehyde to preserve the cellular protein-DNA interactions and nuclei
were prepared. Immunoprecipitation was conducted with IRF4-specific Ab
(M17). Chromatin immunoprecipitation assay was performed in accordance
with the manufacturer’s instructions (SimpleChIP, Cell Signaling Technology).
Detection of the Il9 promoter was performed with the following oligonucleo-
tides: murine IL-9 ChIP 2 forward: 50-GAT TCT CAC AAC CAG AAT TCC
TGC-30; murine IL-9 ChIP 2 reverse: 50-CTA CCA GCA TCT TCC AGT CTA
GC-30. Quantitative RT-PCR with the precipitated chromatin was performed
to calculate the percentage of input. After normalization of the data according
to the respective isotype control, the percent of input chromatin was
calculated.
Asthma Experimental Protocol
Adoptive Transfer Model
BALB/c Rag2/ mice received PBS, 2 3 106 Th2 cells, or 2 3 106 Th9 cells
derived from naive CD4+ T cells from DO11.10 BALB/c mice on day 0 by intra-
venous injection (i.v.). Mice were then challenged via the airways with nebu-
lized OVA (1% in saline) with an ultrasonic nebulizer (NE-U17; Omron, Hoof-
dorp, the Netherlands) for 20 min daily from day 1 to 6. Thirty minutes before
each OVA challenge, mice received either 150mg anti-IL-9 (229.4) or 150mg
of the respective isotype control intra-nasally. On day 7 airway reactivity was
assessed and broncho-alveolar lavage fluid, blood, and lung tissue were
collected on the same day (see Figure S4).200 Immunity 33, 192–202, August 27, 2010 ª2010 Elsevier Inc.Secondary Model of Allergic Airway Disease
Ten- to 12-week-old C57Bl/6 wild-type, Irf4+/ and Irf4/ mice were sensi-
tized by i.p. injection of 20 mg OVA (Grade V; Sigma-Aldrich, St. Louis, MO)
emulsified in 2.25 mg of aluminum hydroxide (AlumImuject; Pierce, Rockford,
IL) in a total volume of 100 ml on days 0 and 14. One day prior to the first chal-
lenge mice received either PBS or 23 106 Th9 cells differentiated in vitro from
naive CD4+ T cells derived from OT-II mice by i.v. injection. Mice were chal-
lenged (20 min) via the airways with OVA (1% in saline) on three consecutive
days (days 28, 29, and 30; challenge) (see Figure S5) with ultrasonic nebuliza-
tion (NE-U17, Omron, Hoofdorp, The Netherlands). Control mice groups
received OVA challenge without prior sensitization. Assays were performed
24 hr after the last challenge on day 31.
Measurement of Airway Reactivity
Measurements of the airway resistance (RL) and dynamic compliance (Cdyn)
were performed on anesthetized, intubated, and mechanically ventilated
mice (FlexiVent, Scireq, Montreal, QC) in response to increasing doses of
inhaled methacholine (MCh) (3.125, 12.5, 25, and 50 mg/ml). Measurements
of RL and Cdyn were performed every 15 s after each nebulization step until
a plateau phase was reached (Reuter et al., 2007).
Broncho-Alveolar Lavage
After assessment of airway function, cells were isolated by lavage of the lungs
via a tracheal tube with PBS (1 3 1 ml). Numbers of BAL cells were counted
with trypan blue dye exclusion. Differential cell counts were made from cyto-
centrifuged preparations fixed and stained with the Microscopy Hemacolor
set (Merck, Darmstadt, Germany). The percentage and absolute numbers of
each cell type were calculated. The numbers of CCR3+Gr1+ eosinophils
were assessed by flow cytometric analysis with anti-Gr1 (clone RB6-8C5,
eBioscience) and anti-CCR3 (clone 83103; Becton Dickinson).
Histology
Lungs were fixed by inflation (1 ml) and immersion in 10% formalin and
embedded in paraffin. Tissue sections were stained with hematoxylin and
eosin (H&E) and periodic acid-Schiff (PAS). Slides were examined in blinded
fashion by two experienced observers with a microscope (BX40, Olympus,
Hamburg, Germany), and peribronchial and perivascular inflammation was
graded by a semiquantitative score (no inflammation = 0 to 4). For each slide,
five randomly chosen areas were scored. With PAS stained slides, the number
of goblet cells was analyzed with imaging software (analysis, Soft Imaging
Systems, Stuttgart, Germany). The number of mucus-containing cells per
millimeter of basement membrane was determined.
Statistical Analysis
ANOVA was used for determining the levels of difference between all groups.
Differences in responsiveness to MCh were assessed by repeated measure-
ments. Comparisons for all pairs were performed by the Tukey-Kramer honest
significant difference test. Number of eosinophils, histology score, and number
of PAS-positive cells were initially analyzed by nonparametric ANOVA
(Kruskal-Wallis Test) for overall differences. In case of significant results,
Mann-Whitney U test was used for elucidating which specific differences
were statistical significant. p values for significance were set at 0.05. Values
for all measurements are expressed as the mean ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and can be found with this
article online at doi:10.1016/j.immuni.2010.07.014.
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